SCHEMBL7868233

SCHEMBL7868233

Cc1nc2cc(-c3ccc4c(c3)CN(C(=O)c3ccc5ccccc5c3)CCC4)ccc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.45
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HSD11B1 P28845 2/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GRM5 P41594 1/20 0.39
ABCB1 P08183 2/20 0.38
AKR1C1 Q04828 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
PKM P14618 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
GHSR Q92847 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SPR P35270 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7860217 0.92 PIK3CA (0.44) PIK3CAHPGDHDAC6HSD11B1KDM4E
SCHEMBL7868232 0.90 PIK3CA (0.47) PIK3CAHPGDHDAC6HSD11B1KDM4E
SCHEMBL7865573 0.89 HDAC6 (0.47) PIK3CAHPGDHDAC6HSD11B1KDM4E
SCHEMBL7864958 0.89 PIK3CA (0.49) PIK3CAHDAC6HSD11B1ABCB1PKM
SCHEMBL7860213 0.89 ABCB1 (0.49) PIK3CAHDAC6HSD11B1ABCB1MEN1
SCHEMBL7866569 0.88 GHSR (0.48) PIK3CAKDM4EGHSR
SCHEMBL7868242 0.87 PIK3CA (0.47) PIK3CAHDAC6HSD11B1KDM4EABCB1
SCHEMBL7871226 0.87 ABCB1 (0.48) PIK3CAHPGDABCB1PKMMEN1
SCHEMBL7870080 0.87 GPR142 (0.47) PIK3CAHPGDHDAC6HSD11B1ABCB1
SCHEMBL7867711 0.86 PIK3CA (0.43) PIK3CAHDAC6HSD11B1ABCB1GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR PIK3CA 16/4885HPGD 1748/4885TSHR 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.